One of the most characteristic features of transdermal therapeutic systems (TTS) is a constant long-term delivery bypassing the first pass metabolism.
50 and 60 mm. The content of GTS-21 free-base was controlled at 0.172 mg/cm 2 . The monolithic TTS devices used for GTS-21 free-base were cut to for each study.
In Vitro Skin Permeation Experiment Excised abdominal skin from male WBN hairless rats (200-220 g, Ishikawa laboratory animal, Saitama, Japan) was used. The abdominal skin was shaven with a BS 5 585 shaver (Brown, Kanagawa, Japan) before the experiment. Either intact skin or stripped skin was mounted on a vertical diffusion cell (Ishii Shoten, Tokyo, Japan). The stripped skin was prepared by stripping the stratum corneum with cellophane tape (Nichiban, Tokyo, Japan) 20 times before excision. The receptor fluid, a 40% (v/v) aqueous solution of polyethylene glycol 400, was maintained at 38.0°C. GTS-21 free-base TTS (2.83 cm 2 ) was placed on the skin and the system was fixed with a cell cap and clamp. The receptor fluid (200 ml) was sampled periodically and the drug concentration was analyzed immediately by HPLC. The assay conditions were as follows: sample size, 20 ml; column, Develosil ODS-HG-5 (Nomura Chemical, Aichi, Japan); column temperature, 40°C; flow rate, 1.3 ml/min; detector, 210 nm; mobile phase, 5 mM NaH 2 PO 4 (adjusted with 1 N NaOH to pH 8.0)-acetonitrile (2 : 1).
Determination of Skin Surface Temperature Skin surface temperature was determined in an in vitro permeation experiment and in hairless rats (i.e. in vivo) by use of a clinical thermometer, CTM-303 (TERUMO, Kanagawa, Japan). Excised skin was set on the vertical diffusion cell as in the in vitro permeation experiment. The probe of the thermometer was placed on the skin and fixed in place with surgical tape (Nichiban, Tokyo, Japan). In the in vivo experiment, the probe was attached to the shaven abdomen with an adhesive bandage (Elastpore, Nichiban, Tokyo, Japan) under ether anesthesia. The temperature was measured when the animal awakened.
Intravenous (i.v.) Administration Male WBN hairless rats (190-220 g) were used. GTS-21 in saline was administered at 1 mg/ml into a tail vein. Blood samples were col-lected from the postcaval vein under ether anesthesia. After the collection of blood, the animal was euthanized immediately. The plasma was separated by centrifugation at 5°C and stored at Ϫ70°C until analysis. The plasma samples were analyzed using a HPLC procedure developed by Azuma et al. 6) Measurement of Skin Thickness Intact (full thickness), stripped (viable) and epidermal skin were sandwiched between polyester sheets. The thickness was measured with a digital micrometer, model MDC-25M (Mitutoyo, Kanagawa, Japan). The epidermal skin was prepared by 12 h immersing the intact skin for 12 h in saline containing 2 M NaBr and 0.01% (w/v) sodium azide.
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In Vivo Percutaneous Experiment Male WBN hairless rats (190-220 g) were used. Before the experiment, the abdominal skin was shaven. GTS-21 free-base TTS (10 cm 2 ) was placed on the abdomen and covered with an adhesive bandage under ether anesthesia. The collection of blood samples and assay of GTS-21 free-base were carried out by the same method used for the i.v. administration experiment. The period of application was 24 h.
Simulation of GTS-21 Free-Base Plasma Concentration
The permeation rate of GTS-21 free-base from TTS varied with time during the administration. Assuming that rate is in proportion to the variation of drug concentration on the surface of the stratum corneum, we predicted the GTS-21 freebase plasma concentration by use of a bi-layer diffusion/twocompartment model. 8, 9) From the time-profile of the cumulative amount of the drug, the instantaneous penetration rate was evaluated as a function of time and the correction factor defined as the ratio of the instantaneous penetration rate to the steady-state penetration rate (J) was then calculated. The drug concentration on the surface of the stratum corneum was also calculated by multiplying the steady-state surface concentration (C s ) and the correction factor determined. Since there is a lag time between the onset of partitioning of the stratum corneum and the partitioning of the receptor compartment, we evaluated the plasma concentration after the lag time of about 1 h for intact skin.
RESULTS AND DISCUSSION
In Vitro Skin Permeation Experiment Before the in vitro permeation experiment, the surface temperature of the skin was measured in vivo and in vitro ( Table 1) .
The temperature of the skin in vitro was 1-2°C lower than that of the receptor fluid. The in vitro percutaneous experiment was therefore performed at 38.0°C, while skin temperature was 36.7°C in vivo. It is sometimes recommended that the surface temperature of in vitro be 32°C, simulating that of normal human skin. 10, 11) But the GTS-21 permeation coefficient was 2.0 times larger at 37.0°C than at 32.0°C in the in vitro skin permeation experiment using a side-by-side cell (not shown).
The in vitro permeation-time profiles for intact and stripped skin are shown in Fig. 1 . After a short lag time, the flux (J) was maintained until 5 h (intact skin). After that time, the permeation rate declined gradually due to a decrease in thermodynamic activity. The cumulative amount of GTS-21 free-base that permeated through the skin over 24 h was 85.17 mg/cm 2 which corresponded to 58% of the GTS-21 free-base in the system. In vitro penetration experiment through stripped skin was also carried out for comparison. The flux (J) and lag time (t d ) evaluated are listed in Table 2 .
We have determined the steady-state surface concentration (C s ), diffusion coefficient (D) and partition coefficient (K) in the skin assuming the bi-layer skin model 12) (Table 3) . D was about 10 3 times smaller in stratum corneum than viable skin. It seems that stratum corneum is the rate-limiting barrier in the permeation of GTS-21 free-base through skin.
By means of the proposed method, the permeation-time profile was calculated by assuming the thickness of intact skin of 354Ϯ30 mm and compared with the in vitro experimental data (Fig. 2) . The calculated profile (solid line) well described the in vitro experimental data (closed square). This may indicate that the modified model can be used to simulate the GTS-21 free-base plasma concentration-time profile. In in vivo percutaneous absorption, on the other hand, the diffusion distance of drug molecules in the skin was assumed to be the depth from the surface of the stratum corneum to capillary blood vessels, 14) approximately identical to the thickness of the epidermis (47Ϯ8 mm (meanϮS.D. of 4 animals)). Therefore, the in vivo permeation profile was also calculated assuming the diffusion distance of GTS-21 free-base to be 47 mm in Fig. 2 (dotted line). i.v. Administration The plasma concentration-time profile of GTS-21 after i.v. administration is shown in Fig. 3 . The pharmacokinetic parameters were then evaluated using an open two-compartment model ( Table 4 ). The plasma concentration declined in a biphasic manner, with a rapid distribution phase (half-life t 1/2,a , 0.189 h) and slightly slow terminal phase (t 1/2,b 0.750 h). This plasma concentration-time profile accorded with that of Sprague-Dawley rats.
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Comparison of the Simulation and in Vivo Percutaneous Experiments The plasma concentration-time profile was calculated by the proposed approach and compared with the results of the in vivo percutaneous experiment in Fig. 4 . The in vivo plasma concentration of GTS-21 free-base decreased rapidly after a sharp rise. In this figure, the solid line indicates the calculated profile assuming the diffusion distance of 47 mm, while the dotted line was predicted for the diffusion distance of 354 mm as described in Fig. 2 . The simulated dotted profile assuming the distance of 47 mm better agreed with the in vivo experimental data. The time to reach C max (T max ) was slightly longer than the in vivo data, and the calculated concentration after C max decreased more slowly than in vivo profile. This may indicate that the rate of decrease in the surface concentration of the stratum corneum is underestimated than in vivo experiment. After about 10 h, the plasma concentrations calculated from this model declined in a same manner as in vitro, indicating the applicability of the present pharmacokinetic model.
If in vitro skin permeation experiments can be performed with human epidermis, and the pharmacokinetic parameters for humans have been already obtained, the clinical concentration may be predicted from the present model together with pharmacokinetic parameters obtained. 
